Predictive factors of treatment outcomes after percutaneous ablation of hepatocellular carcinoma in the caudate lobe: a retrospective study

Table 3 Univariate and multivariate analysis of predictors of LTP after caudate lobe ablation

Factors		Univariate	Multivariate
Factors		P value	HR	95%CI	P value
Gender(M/F)		0.401
Age(≤60/>60y)		0.811
Tumor type (naive/recurrent)		0.846
Surgery history of liver (Y/N)		0.655
Etiology (Hepatitis/others)		0.821
Liver cirrhosis (Y/N)		0.499
Antiviral treatment (Y/N)		0.539
ECOG performance status (0/1)		0.768
Child-Pugh (A/B)		0.998
BCLC stage of primary HCC (A/B)		0.661
AFP (≥400/< 400 μg/L)		0.432
PLT (≥100/< 100 × 10⁹/L)		0.530
PT (≤14/> 14 s)		0.877
ALB (≤35/> 35 g/L)		0.280
ALT (≤40/> 40 IU/L)		0.162
TB (≤17.1/> 17.1 mol/L)		0.616
Tumor number (single /multiple)		0.336
Location (Paracaval portion/ Caudate process/ Spiegel’s lobe)		0.466
Tumor size (≤2 cm /> 2 cm)		0.029	3.667	1.043–12.889	0.043
Puncture approach (LA/ RA/ combination approach)		0.921
Treatment strategy	RFA/ EA/ RFA-EA	0.099	–	–	–
	EA/RFA or RFA-EA	0.223
	RFA or EA/RFA-EA	0.054	–	–	–
AM (≥ 5 mm / < 5 mm)		0.336

HBV hepatitis B virus, HCV hepatitis C virus, ECOG East Coast Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, PLT platelets, PT prothrombin time, ALB albumin, ALT alanine aminotransferase, TB total bilirubin, LA left lobe approach, RA right intercostal approach, EA ethanol ablation, RFA radiofrequency ablation, RFA-EA combination of RFA and EA, AM ablative margin

ISSN: 1471-2407